Forward-looking statements are only predictions and the actual events or results may differ materially. These statements relate to current estimates and assumptions of our management as of the date of this press release and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. These forward-looking statements include, without limitation, statements regarding Natus’s ability to supply screening devices into the future. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. Forward-looking statements can be identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, “will”, “outlook” and similar expressions. This press release contains forward-looking statements, which are generally statements that are not historical facts. Natus is a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages.Īdditional information about Natus Medical can be found at Forward-Looking Statements Installation of ALGO screeners at the Pediatrix hospitals will be completed during 2020.
The transition of the Peloton business is expected to be complete by the end of the fourth quarter of 2019. Hinson, M.D., President of Pediatrix and Obstetrix Medical Groups. “We are excited to add the Peloton customers to our existing portfolio of hospitals benefiting from our leading healthcare solutions, and we believe we can add tremendous value in these new relationships,” said Roger M. “This partnership allows us to continue to supply our world-class screening devices and supplies to the hearing screening business through our strategic agreement with Pediatrix.” “We are pleased to partner with an industry leader like Pediatrix to carry on our practice of newborn hearing screening service into the future,” said Jonathan Kennedy, President and Chief Executive Officer of Natus.
Upon completion of this transition, Pediatrix will provide hearing screening services to over 500 U.S. As part of the transition, Natus and Pediatrix have entered into a strategic agreement where Natus will provide its best-in-class ALGO screeners and supplies to Pediatrix to support its entire hearing screening business. After the completion of the transition, Pediatrix will manage all newborn hearing screening services for Peloton hospitals. 17, 2019 (GLOBE NEWSWIRE) - Natus Medical Incorporated (NASDAQ: NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company signed a definitive agreement to transition its Peloton hearing screening services business to Pediatrix Medical Group (“Pediatrix”).
0 kommentar(er)
